SCHEDULE: Imunon Ownership Update: Ayrton Capital's 0.01% Stake
Beneficial Ownership Report
Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri report a combined 0.01% beneficial ownership in Imunon, Inc. common stock.
Summary
- Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership of Imunon, Inc. common stock.
- Each reporting person beneficially owns 2,000 shares of Imunon, Inc. common stock as of June 30, 2025.
- This ownership represents 0.01% of the class, calculated based on 17,541,732 shares outstanding as of May 16, 2025.
- The reported shares are issuable upon the exercise of certain warrants and conversion of certain convertible notes held by the reporting persons.
- Shares issuable from warrants are subject to a 9.99% beneficial ownership blocker.
- The reported holdings are based on amounts prior to Imunon, Inc.'s reverse stock split in July 2025.
Sentiment
Score: 5
Explanation: The filing is a routine beneficial ownership disclosure (Schedule 13G) and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or outlook. It is purely factual.
Future Outlook
NA
Industry Context
This filing is a standard beneficial ownership disclosure and does not provide information relevant to broader industry trends or competitive analysis. It solely reports a minor ownership stake in Imunon, Inc., a biotechnology company.
Related Party Transactions
- Alto Opportunity Master Fund, SPC Segregated Master Portfolio B is a private investment vehicle for which Ayrton Capital LLC serves as the investment manager.
- Waqas Khatri serves as the managing member of Ayrton Capital LLC and is also a director of Alto Opportunity Master Fund, SPC Segregated Master Portfolio B.
Stakeholder Impact
- Shareholders: Minimal direct impact as the reported ownership is a very small percentage (0.01%) and does not suggest any change in control or significant strategic shift.
- Employees, Customers, Suppliers, Creditors: No direct impact indicated by this beneficial ownership filing.
Key Dates
| Date | Description |
|---|---|
| 2025-05-16 | Date as of which 17,541,732 shares of Common Stock were outstanding, used for percentage calculation. |
| 2025-05-19 | Date of Issuer's Form S-1/A filing, which stated the number of outstanding shares. |
| 2025-06-30 | Date of event requiring filing; holdings reported as of this date. |
| 2025-07-XX | Month of Imunon, Inc.'s reverse stock split, which occurred after the reported holdings date. |
| 2025-08-13 | Date of filing and signature by reporting persons. |
Keywords
Imunon Inc, IMUN, Schedule 13G, Beneficial Ownership, Ayrton Capital, Alto Opportunity Master Fund, Waqas Khatri, Common Stock, Warrants, Convertible Notes, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.